AbbVie 8-K
Guidance reaffirmedImpairment / chargeDeal completedClinical / regulatory decision
Apogee acquisition closes, adding zumilokibart to the immunology pipeline but diluting near-term adjusted EPS.
Filed 2026-09-03 08:47 ET
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
AbbVie completed its acquisition of Apogee Therapeutics for cash, adding its immunology pipeline. The deal is expected to reduce adjusted diluted EPS by $0.14 in 2026 and ≈$0.46 in 2027, with accretion beginning in 2032.
Key Figures
- Purchase price: $135.11 per Apogee share in cash; total equity value ≈$10.9B.
- Zumilokibart, a late-stage IL-13 antibody in development for atopic dermatitis, showed significant skin clearance in ≈two-thirds of treated patients at 16 weeks in a Phase 2 trial; longer-term data supported quarterly or twice-yearly maintenance dosing.
- APG273, an IL-13/TSLP combination in development for asthma, is being evaluated for quarterly or twice-yearly injections.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS, non-GAAP | FY2026 | $13.87-$14.07 | $13.87-$14.07 | Reaffirmed |
| Adjusted diluted EPS, non-GAAP | Q3 2026 | $3.84-$3.88 | $3.84-$3.88 | Reaffirmed |
FY2026 guidance includes $0.14 per share of acquisition-related dilution and $0.58 per share of unfavorable acquired in-process research and development and milestones expense incurred through Q2; it excludes any such expense after Q2. Q3 guidance excludes any acquired in-process research and development and milestones expense in the quarter.
Investor Takeaways
- Progression of zumilokibart and APG273 through clinical development will test the pipeline’s potential.
- Watch whether the acquisition integrates successfully and delivers the expected EPS trajectory, including accretion beginning in 2032.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3